Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 39%? [Yahoo! Finance]
Anika Therapeutics (NASDAQ:ANIK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Anika Reports Third Quarter 2025 Financial Results
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study